Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR; Silymarin in NASH and C Hepatitis (SyNCH) Study Group.

JAMA. 2012 Jul 18;308(3):274-82. doi: 10.1001/jama.2012.8265.

2.

[Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].

Pár A, Roth E, Miseta A, Hegedüs G, Pár G, Hunyady B, Vincze A.

Orv Hetil. 2009 Jan 11;150(2):73-9. doi: 10.1556/OH.2009.28517. Hungarian.

PMID:
19103558
3.

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.

Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM; SyNCH Study Group.

Clin Trials. 2012 Feb;9(1):102-12. doi: 10.1177/1740774511427064. Epub 2011 Nov 4.

4.

Effects of vitamin E on chronic hepatitis C genotype 3: a randomized, double-blind, placebo-controlled study.

Bunchorntavakul C, Wootthananont T, Atsawarungruangkit A.

J Med Assoc Thai. 2014 Nov;97 Suppl 11:S31-40.

PMID:
25509693
5.

Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial.

Gabbay E, Zigmond E, Pappo O, Hemed N, Rowe M, Zabrecky G, Cohen R, Ilan Y.

World J Gastroenterol. 2007 Oct 28;13(40):5317-23.

6.

Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials.

Yang Z, Zhuang L, Lu Y, Xu Q, Chen X.

Biomed Res Int. 2014;2014:941085. doi: 10.1155/2014/941085. Epub 2014 Aug 27. Review.

7.

Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.

Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, Roberts SK.

J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):275-80.

PMID:
16460486
8.

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network.

JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520.

9.

Nitazoxanide for chronic hepatitis C.

Nikolova K, Gluud C, Grevstad B, Jakobsen JC.

Cochrane Database Syst Rev. 2014 Apr 6;(4):CD009182. doi: 10.1002/14651858.CD009182.pub2. Review.

PMID:
24706397
10.

A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis.

El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, Mikhail N, Hashem M, Mousa A, Aboul-Fotouh A, El-Kassas M, Esmat G, Strickland GT.

Phytomedicine. 2009 May;16(5):391-400. doi: 10.1016/j.phymed.2009.02.002. Epub 2009 Mar 19.

11.

Efficacy and tolerability of diphenyl-dimethyl-dicarboxylate plus garlic oil in patients with chronic hepatitis.

Lee MH, Kim YM, Kim SG.

Int J Clin Pharmacol Ther. 2012 Nov;50(11):778-86. doi: 10.5414/CP201746.

PMID:
22943930
12.

Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C.

Guilera M, Forns X, Torras X, Enríquez J, Coll S, Solà R, Morillas R, Planas R, Ampurdanès S, Soler M, Costa J, Sáiz JC, Sánchez-Tapias JM, Rodés J.

J Hepatol. 2000 Jul;33(1):135-41.

PMID:
10905597
13.

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.

Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S.

Lancet. 2015 Jun 20;385(9986):2502-9. doi: 10.1016/S0140-6736(15)60159-3. Epub 2015 Mar 31.

PMID:
25837829
14.
15.

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Berman J, Liu QY, Doo E, Fried MW; SyNCH Trial Group.

J Clin Pharmacol. 2010 Apr;50(4):434-49. doi: 10.1177/0091270009347475. Epub 2009 Oct 19.

16.

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.

Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, Murphy MP.

Liver Int. 2010 Aug;30(7):1019-26. doi: 10.1111/j.1478-3231.2010.02250.x. Epub 2010 May 18.

PMID:
20492507
17.
18.
19.

Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection.

Adeyemo O, Doi H, Rajender Reddy K, Kaplan DE.

J Viral Hepat. 2013 Jul;20(7):453-62. doi: 10.1111/jvh.12050. Epub 2013 Apr 12.

20.

Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.

Xie Y, Xu DZ, Lu ZM, Luo KX, Jia JD, Wang YM, Zhao GZ, Zhang SL, Zhang DZ.

Hepatobiliary Pancreat Dis Int. 2005 May;4(2):213-9.

PMID:
15908318

Supplemental Content

Support Center